the EARLY TREATMENT WITH BAMLANIVIMAB ALONE DOES NOT PREVENT COVID-19 HOSPITALIZATION AND ITS POST-ACUTE SEQUELAE. A REAL EXPERIENCE IN UMBRIA, ITALY.

Background and Objective The use of monoclonal antibodies to the SARS-Cov-2 spike protein for early treatment of COVID-19 disease is being evaluated, with only phase 2 studies available, to date. Emergency authorization of bamlanivimab monotherapy was get in November 2020 by the FDA and in Mar...

Descripció completa

Dades bibliogràfiques

Autors principals:	Elisabetta Schiaroli, Giuseppe Vittorio De Socio, Laura Martinelli Martinelli, lisa malincarne, Martina Savoia, Anna Laura Spinelli, Daniela Francisci
Format:	Artigo
Idioma:	Inglês
Publicat:	PAGEPress Publications 2021-10-01
Col·lecció:	Mediterranean Journal of Hematology and Infectious Diseases
Matèries:	Bamlanivimab COVID-19 hospitalization real experience Umbria
Accés en línia:	http://mjhid.org/index.php/mjhid/article/view/4690
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!